Cancer MDx Firm Nucleix Raises $5M | GenomeWeb

NEW YORK (GenomeWeb) – Israeli epigenetics-based diagnostics firm Nucleix announced on Monday that it has raised more than $5 million in private financing.

The company's lead product is the urine-based Bladder EpiCheck for detecting bladder cancer. The funding will go toward clinical trials for the test, as well as efforts to gain European CE marking and US Food and Drug Administration regulatory approval, Tel Aviv, Israel-based Nucleix said. Funds will also be used to develop diagnostic tests for other cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.